L-Ifosfamide | CAS#66849-34-1 | nitrogen mustard

MedKoo Cat#: 597371 | Name: L-Ifosfamide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

L-Ifosfamide is a nitrogen mustard, a chemotherapeutic antineoplastic and more precisely an alkylating agent structural analogue of cyclophosphamide with respect to which presents some differences with regard to the spectrum and the antitumor activity.

Chemical Structure

L-Ifosfamide

CAS#66849-34-1

Theoretical Analysis

MedKoo Cat#: 597371

Name: L-Ifosfamide

CAS#: 66849-34-1

Chemical Formula: C7H15Cl2N2O2P

Exact Mass: 260.0248

Molecular Weight: 261.08

Elemental Analysis: C, 32.20; H, 5.79; Cl, 27.16; N, 10.73; O, 12.26; P, 11.86

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

(+)-Ifosfamide; L-Ifosfamide;

IUPAC/Chemical Name

(R)-3-(2-chloroethyl)-2-((2-chloroethyl)amino)-1,3,2-oxazaphosphinane 2-oxide

InChi Key

HOMGKSMUEGBAAB-CQSZACIVSA-N

InChi Code

InChI=1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)/t14-/m1/s1

SMILES Code

ClCCN1[P@](OCCC1)(NCCCl)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 261.08 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Bisogno G, Jenney M, Bergeron C, Melcón SG, Ferrari A, Oberlin O, Carli M, Stevens M, Kelsey A, Paoli A, Gaze MN, Martelli H, Devalck C, Merks JH, Ben-Arush M, Glosli H, Chisholm J, Orbach D, Minard-Colin V, De Salvo GL; European paediatric Soft tissue sarcoma Study Group. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet Oncol. 2018 Jun 22. pii: S1470-2045(18)30337-1. doi: 10.1016/S1470-2045(18)30337-1. [Epub ahead of print] PubMed PMID: 29941280. 2: Kálmán J, Horváth T, Liktor B, Liktor B. A unique manifestation of Langerhans cell histiocytosis: Diagnostic and therapeutic considerations of atypical cases. Ear Nose Throat J. 2018 Apr-May;97(4-5):E13-E17. PubMed PMID: 29940687. 3: Arndt CAS, Bisogno G, Koscielniak E. Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned. Cancer Treat Rev. 2018 Jun 19;68:94-101. doi: 10.1016/j.ctrv.2018.06.013. [Epub ahead of print] Review. PubMed PMID: 29940525. 4: Maliszewska O, Plenis A, Olędzka I, Kowalski P, Miękus N, Bień E, Krawczyk MA, Adamkiewicz-Drożynska E, Bączek T. Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies. J Pharm Biomed Anal. 2018 Jun 19;158:376-385. doi: 10.1016/j.jpba.2018.06.031. [Epub ahead of print] PubMed PMID: 29936377. 5: Sundby Hall K, Bruland ØS, Bjerkehagen B, Zaikova O, Engellau J, Hagberg O, Hansson L, Hagberg H, Ahlström M, Knobel H, Papworth K, Zemmler M, Goplen D, Bauer HCF, Eriksson M. Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors-A Scandinavian Sarcoma Group study (SSG XX). Eur J Cancer. 2018 Jun 18;99:78-85. doi: 10.1016/j.ejca.2018.05.011. [Epub ahead of print] PubMed PMID: 29929092. 6: Bakavičius A, Barisienė M, Snicorius M, Valančienė D, Dasevičius D, Žalimas A, Kvaščevičius R, Ramonas H, Sokolovas V, Jankevičius F. Malignant mixed epithelial and stromal tumour of the kidney: a case report and a literature review. Acta Med Litu. 2018;25(1):31-37. doi: 10.6001/actamedica.v25i1.3701. PubMed PMID: 29928155; PubMed Central PMCID: PMC6008004. 7: Elsebaie MAT, Amgad M, Elkashash A, Elgebaly AS, Ashal GGEL, Shash E, Elsayed Z. Management of Low and Intermediate Risk Adult Rhabdomyosarcoma: A Pooled Survival Analysis of 553 Patients. Sci Rep. 2018 Jun 19;8(1):9337. doi: 10.1038/s41598-018-27556-1. PubMed PMID: 29921891; PubMed Central PMCID: PMC6008292. 8: McPhail ED, Maurer MJ, Macon WR, Feldman AL, Kurtin PJ, Ketterling RP, Vaidya R, Cerhan JR, Ansell SM, Porrata LF, Nowakowski GS, Witzig TE, Habermann TM. Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica. 2018 Jun 14. pii: haematol.2018.190157. doi: 10.3324/haematol.2018.190157. [Epub ahead of print] PubMed PMID: 29903764. 9: Panigrahi MK, Pradhan G, Sahoo N, Mishra P, Patra S, Mohapatra PR. Primary pulmonary synovial sarcoma: A reappraisal. J Cancer Res Ther. 2018 Apr-Jun;14(3):481-489. doi: 10.4103/0973-1482.204883. Review. PubMed PMID: 29893303. 10: Yamaguchi M. [Treatment of NK/T-cell lymphoma: current situations and prospectives]. Rinsho Ketsueki. 2018;59(5):588-593. doi: 10.11406/rinketsu.59.588. Japanese. PubMed PMID: 29877250. 11: De Sanctis R, Viganò A, Giuliani A, Gronchi A, De Paoli A, Navarria P, Quagliuolo V, Santoro A, Colosimo A. Unsupervised versus Supervised Identification of Prognostic Factors in Patients with Localized Retroperitoneal Sarcoma: A Data Clustering and Mahalanobis Distance Approach. Biomed Res Int. 2018 Apr 23;2018:2786163. doi: 10.1155/2018/2786163. eCollection 2018. PubMed PMID: 29850497; PubMed Central PMCID: PMC5937625. 12: Nagaharu K, Masuya M, Kageyama Y, Yamaguchi T, Ito R, Kawakami K, Ito M, Katayama N. Successful treatment of primary bone marrow Hodgkin lymphoma with brentuximab vedotin: a case report and review of the literature. J Med Case Rep. 2018 May 30;12(1):151. doi: 10.1186/s13256-018-1693-0. PubMed PMID: 29843820; PubMed Central PMCID: PMC5975584. 13: Wang B, Yao H, Xie X, Yin J, Zou C, Huang G, Shen J. Relationship of peak serum methotrexate concentration to prognosis and drug tolerance in non-metastatic extremity osteosarcomas. Cancer Chemother Pharmacol. 2018 May 28. doi: 10.1007/s00280-018-3592-x. [Epub ahead of print] PubMed PMID: 29808416. 14: Saakyan SV, Tsygankov АY, Moiseeva NI, Karamysheva АF, Zhil'tsova MG, Tadevosyan SS. Retinoblastoma Cell Culturing and Evaluation of Their Drug Resistance. Bull Exp Biol Med. 2018 May;165(1):148-153. doi: 10.1007/s10517-018-4117-7. Epub 2018 May 24. PubMed PMID: 29796815. 15: Fagerstedt KW, Salonen T, Zhao F, Kytölä S, Böhling T, Andersson LC. Establishment of a spontaneously transformed cell line (JU-PI) from a myxoinflammatory fibroblastic sarcoma. Tumour Biol. 2018 May;40(5):1010428318777936. doi: 10.1177/1010428318777936. PubMed PMID: 29788803. 16: Schliemann C, Kerkhoff A, Hesse P, Bröckling S, Hardes J, Streitbürger A, Andreou D, Gosheger G, Elges S, Wardelmann E, Hartmann W, Mesters R, Lenz G, Willich N, Kriz J, Eich H, Berdel WE, Kessler T. Adjuvant chemotherapy-Radiotherapy-Chemotherapy sandwich protocol in resectable soft tissue sarcoma: An updated single-center analysis of 104 cases. PLoS One. 2018 May 22;13(5):e0197315. doi: 10.1371/journal.pone.0197315. eCollection 2018. PubMed PMID: 29787570; PubMed Central PMCID: PMC5963910. 17: Chowdhary M, Sen N, Jeans EB, Miller L, Batus M, Gitelis S, Wang D, Abrams RA. Neoadjuvant Interdigitated Chemoradiotherapy Using Mesna, Doxorubicin, and Ifosfamide for Large, High-grade, Soft Tissue Sarcomas of the Extremity: Improved Efficacy and Reduced Toxicity. Am J Clin Oncol. 2018 May 18. doi: 10.1097/COC.0000000000000467. [Epub ahead of print] PubMed PMID: 29782358. 18: Shin W, Lee HJ, Yang SJ, Paik ES, Choi HJ, Kim TJ, Choi CH, Lee JW, Bae DS, Kim BG. Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer. Obstet Gynecol Sci. 2018 May;61(3):352-358. doi: 10.5468/ogs.2018.61.3.352. Epub 2018 May 9. PubMed PMID: 29780777; PubMed Central PMCID: PMC5956118. 19: Blay JY. Getting up-to-date in the management of soft tissue sarcoma. Future Oncol. 2018 May;14(10s):3-13. doi: 10.2217/fon-2018-0074. PubMed PMID: 29768050. 20: Inoue Y, Nakamura T, Nakanishi H, Oishi M, Hongo F, Okihara K, Mizutani S, Kuroda J, Ukimura O. Therapy-related acute myeloid leukemia and myelodysplastic syndrome among refractory germ cell tumor patients. Int J Urol. 2018 May 11. doi: 10.1111/iju.13597. [Epub ahead of print] PubMed PMID: 29752743.